Abstract 170P
Background
Monocyte-derived macrophages (mo-macs) and polymorphonuclear leukocytes (PMNs) are abundant in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), limiting response to immune checkpoint blockade (ICB) by promoting an immunosuppressive tumor microenvironment (TME). Preclinical work shows that tumor-derived CCR2 ligands and IL8 play a key role in recruiting mo-macs and PMNs, respectively, to the TME. Disrupting these signaling pathways augments ICB in mouse models, but clinical benefit has yet to be observed.
Methods
This phase IIa trial assessed the efficacy of BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8) administered with nivolumab (NIVO) over 4 weeks prior to resection. NSCLC patients were treated with NIVO and CCR2/5i (arm A) or NIVO and anti-IL8 (arm B). HCC patients were treated with NIVO (arm C), NIVO and CCR2/5i (arm D), or NIVO and anti-IL8 (arm E). Primary endpoints were major pathologic response (≤10% viable tumor) for NSCLC and significant tumor necrosis (>70% necrosis) for HCC. Secondary endpoints were safety/tolerability, time to surgery (TTS), and radiographic response.
Results
36 patients were enrolled from March 2020-August 2023; 14 were treated with NIVO and CCR2/5i, 16 with NIVO and anti-IL8, and 6 with NIVO. CCR2/5i and anti-IL8 were safe/tolerated (dose-limiting toxicities or grade 3/4 treatment-related adverse events). 32 of 36 patients underwent resection (mean TTS of 34.8 days). 3 patients met the primary endpoints: 2 in arm B and 1 in arm D. In patients treated with CCR2/5i, serum concentration of CCR2/5 ligands increased, and number of circulating monocytes decreased, after treatment. In patients treated with anti-IL8, serum concentration of IL8 decreased after treatment; however, number of circulating PMNs was not affected. Tissue analysis with scRNA-seq and multiplex imaging is ongoing to elucidate the biologic effects of these agents.
Conclusions
Although CCR2/5i and anti-IL8 appear to be biologically active and exert effects on chemokine levels, they fail to significantly augment the role of ICB in the preoperative setting, contrary to preclinical evidence.
Clinical trial identification
NCT04123379.
Legal entity responsible for the study
The authors.
Funding
CIMAC-CIDC, PACT.
Disclosure
S. Gnjatic: Financial Interests, Personal and Institutional, Funding, Unrelated to Current Work: Regeneron Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, EMD Serono, Pfizer, and Takeda. M. Merad: Financial Interests, Personal, Advisory Board: Compugen Inc., Myeloid Therapeutics Inc., Morphic Therapeutic Inc., Asher Bio Inc., Dren Bio Inc., Nirogy Inc., Oncoresponse Inc., Owkin Inc., Larkspur Inc., Innate Pharma Inc., DBV Inc., Pionyr Inc., OSE Inc., Genenta Inc.; Financial Interests, Personal, Stocks/Shares: Compugen Inc., Myeloid Therapeutics Inc., Morphic Therapeutic Inc., Asher Bio Inc., Dren Bio Inc., Nirogy Inc., Oncoresponse Inc., Owkin Inc., and Larkspur Inc.; Financial Interests, Personal and Institutional, Funding: Regeneron Inc. and Boehringer Ingelheim Inc. T.U. Marron: Financial Interests, Personal, Advisory Board: Rockefeller University, Regeneron Pharmaceuticals, AbbVie, Bristol Meyers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, Glenmark, Simcere, Surface, G1 Therapeutics, NGMbio, DBV Technologies, Arcus, and Astellas; Financial Interests, Personal and Institutional, Funding: Regeneron, Bristol Myers Squibb, Merck, and Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
60P - Adaptive NK cells as a therapeutic option for childhood leukaemia
Presenter: Zoya Eskandarian
Session: Poster Display
61P - Unlocking the Power of Natural Killer Cells: Precision Selection with Cutting-Edge Microfluidics
Presenter: Neelima KC
Session: Poster Display
63TiP - A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen: MIZAR trial
Presenter: Qing Xu
Session: Poster Display
68P - Real-world (rw) outcomes in patients (pts) with metastatic (m) NSCLC and STK11, KEAP1 and/or KRAS mutations (mut) receiving PD-(L)1-based treatment (tx): CORRELATE
Presenter: Solange Peters
Session: Poster Display
70P - LIST (Lung Initiative on Sequence Therapy), a real-world study of nivolumab for advanced NSCLC in France: first effectiveness, safety, and IO-rechallenge results
Presenter: Benoît GODBERT
Session: Poster Display
72P - Camrelizumab plus apatinib after chemoradiotherapy in unresectable stage III non-small-cell lung cancer?A multi-center, single-arm, phase 2 study
Presenter: Hui Zhouguang
Session: Poster Display
74P - A single-center, Phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
Presenter: Wen Feng Fang
Session: Poster Display
75P - Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation
Presenter: Ana Baramidze
Session: Poster Display